Life Sciences Hub
In our blog dedicated to Life Sciences, we report on EU and national regulatory, compliance, intellectual property and transactional developments in the sector.
We focus on (bio)pharmaceuticals and medical technologies, and also cover food and beverages, cosmetics and other healthcare products.
If you have questions about the blog or suggestions about what we should cover please do contact us.
Blog Post: 23 May 2023
PTAB decision invalidating claims as obvious based on analogous art reversed by Federal Circuit
Procedural History Sanofi-Aventis Deutschland GMBH v. Mylan Pharmaceuticals Inc. is an appeal from a final written decision in an inter partes proceeding (“IPR”) of the Patent Trial and Appeal Board…Read more PTAB decision invalidating claims as obvious based on analogous art reversed by Federal Circuit
Blog Post: 22 May 2023
United States Supreme Court affirms invalidating claims for lack of enablement
Executive Summary In Amgen Inc. v. Sanofi, the United States Supreme Court affirmed the lower courts’ judgment that the asserted claims of U.S. Patent No. 8,829,165 (“the ’165 Patent”) and U.S. Patent…Read more United States Supreme Court affirms invalidating claims for lack of enablement